Impact of remote ischemic preconditioning on the T-lymphocyte mitochondrial damage index: a randomized clinical trial

Background: The role of remote ischemic preconditioning (RIPC) in coronary heart disease patients remains uncertain. This study was aimed to assess the RIPC influence on T-lymphocyte mitochondrial damage index (MDI), high-sensitivity troponin-T (hs-TnT) concentration, and the perioperative incidence of adverse events in ST-segment elevation myocardial infarction (STEMI) patients having exceeded the window for emergency reperfusion therapy. Furthermore, the goal was to determine myocardial protective effects of RIPC and investigate its underlying mechanisms. Methods: STEMI patients having surpassed the reperfusion therapy time window were randomly assigned to RIPC (n = 32) and control (n = 32) groups. RIPC group underwent upper limb RIPC (four cycles of 5-min cuff inflation to 200 mmHg followed by 5-min of deflation). T-lymphocyte MDI and hs-TnT concentrations were determined once on admission, and then 2 hours before the percutaneous coronary intervention (PCI), conducted after 10 days. Perioperative incidence for no-reflow, cardiac rupture and malignant arrhythmias were recorded. Results: T-lymphocyte MDI and hs-TnT concentrations upon admission did not differ much in both groups, however, there was a decrease after 10 days, and of greater magnitude in RIPC group. Conclusions: RIPC group exhibited lower incidence of no-reflow during PCI compared to that of control (p = 0.03). RIPC has the potential to mitigate perioperative myocardial injuries in STEMI patients by reducing T-lymphocyte MDI, inhibiting myocardial cell death, and lowering no-reflow risk during PCI. Clinical Trial Registration: Registered website: https://clinicaltrials.gov/search?cond=NCT04766749. Registered number: NCT04766749. Registered date: 10/02/2021.

Acute myocardial infarction; Remote ischemic preconditioning; Mitochondrial damage; T-lymphocytes; Percutaneous coronary intervention

[1] Pantea-Roșan LR, Bungau SG, Radu A-F, Pantea VA, Moisi MI, Vesa CM, et al. A narrative review of the classical and modern diagnostic methods of the no-reflow phenomenon. Diagnostics. 2022; 12: 932.

[2] Niccoli G, Montone RA, Ibanez B, Thiele H, Crea F, Heusch G, et al. Optimized treatment of ST-elevation myocardial infarction. Circulation Research. 2019; 125: 245–258.

[3] Sun X, Feng Y, Gong C, Bao X, Wei Z, Chang L, et al. Hypertension-driven regulatory T-cell perturbations accelerate myocardial ischemia-reperfusion injury. Hypertension. 2023; 80: 2046–2058.

[4] Li C, Wang G, Sivasami P, Ramirez RN, Zhang Y, Benoist C, et al. Interferon-α-producing plasmacytoid dendritic cells drive the loss of adipose tissue regulatory T cells during obesity. Cell Metabolism. 2021; 33: 1610–1623.e5.

[5] Abbate A, Bussani R, Liuzzo G, Biondi-Zoccai GGL, Barresi E, Mellone P, et al. Sudden coronary death, fatal acute myocardial infarction and widespread coronary and myocardial inflammation. Heart. 2008; 94: 737–742.

[6] Yan W-W, Zhang K-S, Duan Q-L, Wang LM. Significantly reduced function of T cells in patients with acute arterial thrombosis. Journal of Geriatric Cardiology. 2015; 12: 287–293.

[7] Bawamia B, Spray L, Wangsaputra VK, Bennaceur K, Vahabi S, Stellos K, et al. Activation of telomerase by TA-65 enhances immunity and reduces inflammation post myocardial infarction. GeroScience. 2023; 45: 2689–2705.

[8] Hu A, Li F, Guo L, Zhao X, Xiang X. Mitochondrial damage of lymphocytes in patients with acute relapse of schizophrenia: a correlational study with efficacy and clinical symptoms. Neuropsychiatric Disease and Treatment. 2022; 18: 2455–2466.

[9] Titus AS, Sung E-A, Zablocki D, Sadoshima J. Mitophagy for cardioprotection. Basic Research in Cardiology. 2023; 118: 42.

[10] Scaini G, Mason BL, Diaz AP, Jha MK, Soares JC, Trivedi MH, et al. Dysregulation of mitochondrial dynamics, mitophagy and apoptosis in major depressive disorder: does inflammation play a role? Molecular Psychiatry. 2022; 27: 1095–1102.

[11] Pang L-X, Cai W-W, Chen L, Fu J, Xia CX, Li JY, et al. The diagnostic value of mitochondrial mass of peripheral T lymphocytes in early sepsis. Frontiers in Public Health. 2022; 10: 928306.

[12] Yu F, Hao Y, Zhao H, Xiao J, Han N, Zhang Y, et al. Distinct mitochondrial disturbance in CD4+T and CD8+T cells from HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes. 2017; 74: 206–212.

[13] Liu G, Lv Y, Wang Y, Xu Z, Chen L, Chen S, et al. Remote ischemic preconditioning reduces mitochondrial apoptosis mediated by calpain 1 activation in myocardial ischemia-reperfusion injury through calcium channel subunit Cacna2d3. Free Radical Biology and Medicine. 2024; 212: 80–93.

[14] Anttila T, Herajärvi J, Laaksonen H, Mustonen C, Honkanen H, Y. Dimova E, et al. Remote ischemic preconditioning and hypoxia-induced biomarkers in acute myocardial infarction: study on a porcine model. Scandinavian Cardiovascular Journal. 2023; 57: 2251730.

[15] Zhao Z, Shi Q, Guo Q, Peng L, Li X, Rao L, et al. Remote ischemic preconditioning can extend the tolerance to extended drug-coated balloon inflation time by reducing myocardial damage during percutaneous coronary intervention. International Journal of Cardiology. 2022; 353: 3–8.

[16] Carrasco-Chinchilla F, Muñoz-García AJ, Domínguez-Franco A, Millán-Vázquez G, Guerrero-Molina A, Ortiz-García C, et al. Remote ischaemic postconditioning: does it protect against ischaemic damage in percutaneous coronary revascularisation? Randomised placebo-controlled clinical trial. Heart. 2013; 99: 1431–1437.

[17] Zhao Z-Z, Li E, Li X-J, Guo Q, Shi QB, Li MW. Effects of remote ischemic preconditioning on coronary blood flow and microcirculation. BMC Cardiovascular Disorders. 2023; 23: 404.

[18] Guo Q, Zhao Z, Yang F, Zhang Z, Rao X, Cui J, et al. Chronic remote ischemic conditioning treatment in patients with chronic stable angina (EARLY-MYO-CSA): a randomized, controlled proof-of-concept trial. BMC Medicine. 2023; 21: 324.

[19] Pryds K, Nielsen RR, Jorsal A, Hansen MS, Ringgaard S, Refsgaard J, et al. Effect of long-term remote ischemic conditioning in patients with chronic ischemic heart failure. Basic Research in Cardiology. 2017; 112: 67.

[20] Kumar V, Prabhu SD, Bansal SS. CD4+ T-lymphocytes exhibit biphasic kinetics post-myocardial infarction. Frontiers in Cardiovascular Medicine. 2022; 9: 992653.

[21] Gadhamsetty S, Marée AM, Beltman J, de Boer R. A general functional response of cytotoxic T lymphocyte-mediated killing of target cells. Biophysical Journal. 2014; 106: 1780–1791.

[22] McKinstry KK, Strutt TM, Swain SL. Regulation of CD4+ T-cell contraction during pathogen challenge. Immunological Reviews. 2010; 236: 110–124.

[23] Zhou L, Chong MMW, Littman DR. Plasticity of CD4+ T cell lineage differentiation. Immunity. 2009; 30: 646–655.

[24] Luo W, Bian X, Liu X, Zhang W, Xie Q, Feng L. A new method for the treatment of myocardial ischemia-reperfusion injury based on γδT cell-mediated immune response. Frontiers in Cardiovascular Medicine. 2023; 10: 1219316.

[25] Baban B, Yin L, Qin X, Liu JY, Shi X, Mozaffari MS. The role of GILZ in modulation of adaptive immunity in a murine model of myocardial infarction. Experimental and Molecular Pathology. 2017; 102: 408–414.

[26] Li D, Gao S. The interplay between T lymphocytes and macrophages in myocardial ischemia/reperfusion injury. To be published in Molecular and Cellular Biochemistry. 2023. [Preprint].

[27] Zaidi Y, Aguilar EG, Troncoso M, Ilatovskaya DV, DeLeon-Pennell KY. Immune regulation of cardiac fibrosis post myocardial infarction. Cellular Signalling. 2021; 77: 109837.

[28] Li C, Zong W, Zhang M, Tu Y, Zhou Q, Ni M, et al. Increased ratio of circulating T-helper 1 to T-helper 2 cells and severity of coronary artery disease in patients with acute myocardial infarction: a prospective observational study. Medical Science Monitor. 2019; 25: 6034–6042.

[29] Hofmann U, Frantz S. Role of T-cells in myocardial infarction. European Heart Journal. 2016; 37: 873–879.

[30] Bansal SS, Ismahil MA, Goel M, Zhou G, Rokosh G, Hamid T, et al. Dysfunctional and proinflammatory regulatory T-lymphocytes are essential for adverse cardiac remodeling in ischemic cardiomyopathy. Circulation. 2019; 139: 206–221.

[31] Feng G, Bajpai G, Ma P, Koenig A, Bredemeyer A, Lokshina I, et al. CCL17 aggravates myocardial injury by suppressing recruitment of regulatory T cells. Circulation. 2022; 145: 765–782.

[32] Gao Z, Xu X, Li Y, Sun K, Yang M, Zhang Q, et al. Mechanistic insight into PPARγ and Tregs in atherosclerotic immune inflammation. Frontiers in Pharmacology. 2021; 12: 750078.

[33] Valikeserlis I, Athanasiou A, Stakos D. Cellular mechanisms and pathways in myocardial reperfusion injury. Coronary Artery Disease. 2021; 32: 567–577.

[34] Lisci M, Griffiths GM. Arming a killer: mitochondrial regulation of CD8+ T cell cytotoxicity. Trends in Cell Biology. 2023; 33: 138–147.

[35] Baixauli F, Acín-Pérez R, Villarroya-Beltrí C, Mazzeo C, Nuñez-Andrade N, Gabandé-Rodriguez E, et al. Mitochondrial respiration controls lysosomal function during inflammatory T cell responses. Cell Metabolism. 2015; 22: 485–498.

[36] Ahmed RM, Mohamed EA, Ashraf M, Maithili S, Nabil F, Rami R, et al. Effect of remote ischemic preconditioning on serum troponin T level following elective percutaneous coronary intervention. Catheterization and Cardiovascular Interventions. 2013; 82: E647–E653.

[37] Heusch G. The coronary circulation as a target of cardioprotection. Circulation Research. 2016; 118: 1643–1658.

[38] Luo SJ, Zhou YJ, Shi DM, Ge HL, Wang JL, Liu RF. Remote ischemic preconditioning reduces myocardial injury in patients undergoing coronary stent implantation. Canadian Journal of Cardiology. 2013; 29: 1084–1089.

[39] Gaspar A, Lourenço AP, Pereira MÁ, Azevedo P, Roncon-Albuquerque R, Marques J, et al. Randomized controlled trial of remote ischaemic conditioning in ST-elevation myocardial infarction as adjuvant to primary angioplasty (RIC-STEMI). Basic Research in Cardiology. 2018; 113: 14.

[40] Hausenloy DJ, Kharbanda RK, Møller UK, Ramlall M, Aarøe J, Butler R, et al. Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial. The Lancet. 2019; 394: 1415–1424.

[41] Pei H, Wu Y, Wei Y, Yang Y, Teng S, Zhang H. Remote ischemic preconditioning reduces perioperative cardiac and renal events in patients undergoing elective coronary intervention: a meta-analysis of 11 randomized trials. PLOS ONE. 2014; 9: e115500.